Compare Teradyne, Inc. (TER) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Teradyne, Inc. trades at $404.24 (market cap $59.34B), while State Street SPDR S&P Biotech ETF trades at $159.61. The key difference: Teradyne, Inc. pays a 0.14% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Teradyne, Inc. nearer its low. Which is the better fit depends on your goals.
| TER | XBI | |
|---|---|---|
Market Cap | $59.34B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $483.84 | $164.28 |
52-Week Low | $109.30 | $86.92 |
Enterprise Value | $59.09B | — |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teradyne (TER) trades at $365.10, down 3.75% on the day despite strong Q2 2026 earnings that beat expectations with EPS of $2.47 versus $2.09 forecast. The stock shows neutral technical signals with support at $358 and resistance at $380, while fundamentals remain robust with 25.77% net margins and 36.66% ROE. Recent news highlights AI-driven semiconductor test demand fueling record revenues.
Outlook remains positive with analyst consensus price target of $481.63 (32% upside) and no sell ratings. Key risks include premium valuation (P/E 52.14) and dependence on semiconductor cycle volatility. Strong institutional ownership and consistent earnings beats support bullish sentiment for long-term growth in AI and robotics markets.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
